


The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently Amended): A compound comprising ~~Compounds of~~ formula (I):



wherein

R1 is a hydrogen atom, a heteroalkyl, heteroaralkyl, heterocycloalkyl, hydroxy or alkyloxy group, R2 is a hydrogen atom or a hydroxy group, or R1 and R2 together are part of a 5- or 6-membered ring;

R3 is a hydrogen atom, a hydroxy, alkyloxy, amino, alkylamino or dialkylamino group or a halogen atom;

R4 and R5 are, each independently of the other, a hydrogen atom, a halogen atom, a hydroxy, amino, nitro or thiol group, an alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical or a glycosyloxy group;

R6 is an alkyl, heteroalkyl, heteroaralkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl or aryl group, R6 not being a group of formula -CHR8-CO-NR9R9', wherein R8, R9 and

R9' are, each independently of the others, a hydrogen atom, an alkyl, heteroalkyl, heteroaralkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl or aryl group, or R9 and R9' together are part of a heterocycloalkyl or heteroaryl ring system, and

X is a group of formula NR<sub>7</sub>, O, S, SO, SO<sub>2</sub>, SO<sub>2</sub>NH, PO<sub>2</sub>NH, CH<sub>2</sub>, CHMe or CO, R<sub>7</sub> being a hydrogen atom, an alkyl or aralkyl group;

or a pharmacologically acceptable salt, solvate, hydrate or pharmacologically acceptable formulation thereof.

2. (Original): Compounds according to claim 1, wherein R<sub>1</sub> is a hydrogen atom.
3. (Currently Amended): Compounds according to claim 1-~~or 2~~, wherein R<sub>2</sub> is a hydrogen atom.
4. (Currently Amended): Compounds according to ~~one of~~ claims 1-~~to~~ 3, wherein R<sub>3</sub> is a hydrogen atom or a hydroxy group.
5. (Currently Amended): Compounds according to ~~one of~~ claims 1-~~to~~ 4, wherein R<sub>4</sub> is a hydrogen atom, an -OH, -OCH<sub>2</sub>COOH, -COOH, -OCH<sub>2</sub>COOCH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub>alkyloxy or glycosyloxy group or a halogen atom.
6. (Currently Amended): Compounds according to ~~one of~~ claims 1-~~to~~ 4, wherein R<sub>4</sub> is a β-D-glucosyloxy group.
7. (Currently Amended): Compounds according to ~~one of~~ claims 1-~~to~~ 6, wherein R<sub>5</sub> is a hydrogen atom, an -OH, -OCH<sub>2</sub>COOH, -COOH, -OCH<sub>2</sub>COOCH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub>alkyloxy or glycosyloxy group or a halogen atom.
8. (Currently Amended): Compounds according to ~~one of~~ claims 1-~~to~~ 6, wherein R<sub>5</sub> is a hydrogen atom.

9. (Currently Amended): Compounds according to ~~one of claims 1 to 8~~, wherein X is an NH group.
10. (Currently Amended): Pharmaceutical compositions comprising a compound according to claims 1 ~~to 9~~ as active ingredient and, optionally, carrier substances and/or adjuvants.
11. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10 in~~ A method for inhibiting factor Xa by administering a compound of claim 1.
12. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10 in~~ A method for the treatment and/or prevention of thromboembolic conditions, arterial restenosis, septicaemia, cancer, acute inflammation or other conditions mediated by factor Xa activity comprising administering a compound of claim 1.
13. (Currently Amended): ~~Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10~~ A method for utilisation preventing or reducing complications relating to thromboembolic conditions in vascular surgery comprising administering a compound of claim 1 prior to, during or following said surgery.